15,932 Shares in Castle Biosciences, Inc. $CSTL Acquired by Diversify Advisory Services LLC

Diversify Advisory Services LLC bought a new stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 15,932 shares of the company’s stock, valued at approximately $389,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of CSTL. BlackRock Inc. purchased a new position in shares of Castle Biosciences in the 2nd quarter worth $78,513,000. Vanguard Group Inc. increased its position in Castle Biosciences by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company’s stock valued at $85,573,000 after acquiring an additional 27,511 shares during the last quarter. RTW Investments LP bought a new position in Castle Biosciences in the fourth quarter valued at about $82,283,000. Principal Financial Group Inc. lifted its holdings in Castle Biosciences by 0.7% in the fourth quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company’s stock valued at $70,317,000 after acquiring an additional 13,289 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Castle Biosciences by 7.0% in the third quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company’s stock worth $33,564,000 after purchasing an additional 96,084 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Derek J. Maetzold sold 20,356 shares of the stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $31.11, for a total value of $633,275.16. Following the completion of the sale, the insider directly owned 21,479 shares of the company’s stock, valued at $668,211.69. This represents a 48.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kristen M. Oelschlager sold 8,587 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $20.71, for a total transaction of $177,836.77. Following the sale, the chief operating officer owned 30,460 shares in the company, valued at $630,826.60. The trade was a 21.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 136,305 shares of company stock worth $3,841,714 over the last three months. 6.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on CSTL. BTIG Research increased their price objective on shares of Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Wall Street Zen raised shares of Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings upgraded shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. Roth Capital began coverage on shares of Castle Biosciences in a research note on Wednesday, June 24th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Zacks Research downgraded shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Castle Biosciences Stock Up 1.9%

CSTL stock opened at $32.93 on Friday. Castle Biosciences, Inc. has a twelve month low of $17.72 and a twelve month high of $44.28. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.01 billion, a P/E ratio of -49.89 and a beta of 0.98. The business’s 50-day moving average price is $25.64 and its 200-day moving average price is $25.47.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The company had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. On average, equities research analysts forecast that Castle Biosciences, Inc. will post -1.29 EPS for the current year.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.